

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

200005455-1

This copy - for
reference only.

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/14, A61K 31/445	A1	(11) International Publication Number: WO 99/50247 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/US99/07057 (22) International Filing Date: 31 March 1999 (31.03.99) (30) Priority Data: 60/080,133 31 March 1998 (31.03.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/080,133 (CON) Filed on 31 March 1998 (31.03.98) (71) Applicant (for all designated States except US): ACADIA PHARMACEUTICALS, INC. [US/US]; 3911 Sorrento Valley Boulevard, San Diego, CA 92121 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BRANN, Mark, Robert [US/US]; 12805 Caminito Boso, San Diego, CA 92130 (US). MESSIER, Terri [US/US]; Apartment 3, 208 North Avenue, Burlington, VT 05401 (US). CURRIER, Erika, Anne [US/US]; Unit B, 12686 Springbrook Drive, San Diego, CA 92130 (US). DUGGENTO, Katharan, Lauri [US/US]; 4170 Via Candidiz #192, San Diego, CA 92128 (US). FRIBERG, Mikael [DK/SE]; Kamnarsvägen 5F231,	S-226 46 Lund (SE). SKJAERBAEK, Niels [DK/DK]; Fagerparken 33, DK-2950 Vedback, Copenhagen (DK). SPALDING, Tracy [DK/US]; 3834 Creststone Place, San Diego, CA 92130 (US). (74) Agents: BURKE, John, E. et al.; Pillsbury Madison & Sutro LLP, 1100 New York Avenue, N.W., Washington, DC 20005 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS		
(57) Abstract		
Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.		